Aricept

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

MigraineCognitive ImpairmentAlzheimer DiseaseDementiaDown Syndrome

357 competitors in Migraine

#DrugCompanyPhaseTrials

1

Aricept

Eisai

Approved

12

Bayer Aspirin

Bayer

Preclinical

23

Savella

AbbVie

Preclinical

24

Cervidil

Pfizer

Preclinical

15

Cymbalta

Alnylam Pharmaceuticals

Preclinical

16

Viagra

VViatris Specialty LLC

Preclinical

27

Pristiq

PPrism Pharmaceuticals

Preclinical

18

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

19

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Preclinical

110

Non-Steroidal Anti-Inflammatory Drugs (NSAID)

Roche

Preclinical

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer's Disease4 trials

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients

Completed·Eisai··NCT02158910·2,231 enrolled

Functional Brain Imaging of Medication Treatment Response in Mild Alzheimer's Disease Patients

Terminated·—·Phase 4·NCT00369603·4 enrolled

Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease

Unknown status·SShanghai Mental Health Center·Phase 3·NCT03283059·600 enrolled

Show 1 more trial

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Unknown status·NNational Center for Research Resources (NCRR)·Phase 2·NCT00031018

Fasting Conditions3 trials

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Non-Fasting Conditions

Completed·Teva·Phase 1·NCT01260948·26 enrolled

Donepezil 10 mg Tablets Under Fasting Conditions

Completed·Teva·Phase 1·NCT01439230·36 enrolled

10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.

Completed·Teva·Phase 1·NCT01260922·26 enrolled

Clinical Trial3 trials

Phase 1 Clinical Trial to Evaluate the Safety, PK and PD of DA-5207 TDS in Healthy Adults

Unknown status·DDong-A ST Co., Ltd.·Phase 1·NCT04479865·49 enrolled

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Active, not recruiting·IInventage Lab., Inc.·Phase 1/2·NCT05345509·62 enrolled

Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Completed·DDong-A ST Co., Ltd.·Phase 1·NCT05127746·51 enrolled

Dementia2 trials

An Efficacy and Safety Study of INM-176 for the Treatment of Patients With Alzheimer Type Dementia

Completed·WWhanin Pharmaceutical Company·Phase 3·NCT01245530·280 enrolled

The Efficacy, Tolerability and Safety of Donepezil (Aricept) in Parkinson's Disease Patients With Dementia

Completed·Eisai·Phase 3·NCT00165815

Fed2 trials

Donepezil 10 mg Tablets Under Fed Conditions

Completed·Teva·Phase 1·NCT01439243·26 enrolled

Bioequivalence Study for Donepezil Hydrochloride Tablets 10 mg Under Fed Condition

Completed·—·Phase 1·NCT01504516·25 enrolled

10 more indications

Down syndrome2 trials

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17

Terminated·Eisai·Phase 3·NCT00754052·8 enrolled

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

Terminated·Eisai·Phase 3·NCT00754013·9 enrolled

Cognitive impairment2 trials

A 28-Week Open Label Extension Study Evaluating Safety and Tolerability of Donepezil Hydrochloride in Subjects With Mild Cognitive Impairment

Completed·Eisai·Phase 4·NCT00934375·145 enrolled

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Completed·Eisai·Phase 2·NCT00103948·165 enrolled

Migraine1 trial

An Evaluation Of The Efficacy And Safety Of Donepezil Hydrochloride (E2020) In Migraine Prophylaxis

Completed·Eisai·Phase 2·NCT01146509·89 enrolled

Moderate to Severe Alzheimer's Disease1 trial

Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease

Completed·Eisai·Phase 3·NCT00478205·1,467 enrolled

Alzheimer disease1 trial

Electrophysiologic Measures of Treatment Response in Alzheimer Disease

Completed·UUS Department of Veterans Affairs·Phase 4·NCT00018278

Phase 11 trial

A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®

Completed·CCorium, Inc.·Phase 1·NCT02968719·107 enrolled

Mild to Moderate Alzheimer's Disease1 trial

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

Completed·Eisai·Phase 4·NCT00230568·100 enrolled

Liver1 trial

A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®

Completed·CCorium, Inc.·Phase 1·NCT03259958·86 enrolled

MPA1 trial

Pharmacokinetic Study of 5 and 10 mg Corplex™ Donepezil TDS Compared to 10 mg Aricept® in Healthy Volunteers

Completed·CCorium, Inc.·Phase 1·NCT04617782·60 enrolled

Unspecified1 trial

Bioequivalence Study for Donepezil Hydrochloride 10 mg Tablets Under Fasting Condition

Completed·—·Phase 1·NCT01504503·26 enrolled

Details

Drug Info

Related News